OIT Software Licensing is evaluating the current and prospective usage of JMP Clinical.
JMP Clinical software from SAS shortens the drug development process by streamlining the exploration, review and submission of clinical trial data. With a visual, information-seeking approach that links advanced analytics with graphics, JMP Clinical offers the thorough and efficient exploration needed in a modern review environment. JMP Clinical uses globally recognized CDISC data to generate reports – including patient profiles and narratives – for submission to the US Food and Drug Administration. It combines JMP, already a popular tool of choice for medical reviewers, and SAS, the standard analysis and reporting tool for biostatisticians in the pharma industry.
The desktop software depicts analysis results visually, so you can spot trends that spreadsheets and static tables tend to hide. It permits clustering of events, interventions and findings and offers effortless access to the statistical details behind the graphics, a benefit not found in similar offerings.
JMP Clinical is designed for medical reviewers, medical writers, data monitors and biostatisticians engaged in analyzing safety data from clinical trials.
JMP Clinical has been requested through our new software evaluation request form (http://oit.duke.edu/comp-print/software/request/it_request.php) for central funding/distribution, and we put together a wiki with some information on the software and some of the purchase options.
If your department currently uses this software or if you are interested in using this software or have considered purchasing this before, we invite you to visit the wiki and comment on it. The information that we collect in this manner will help us determine whether or not central funding and distribution would be beneficial to the Duke community.
Wiki: https://wiki.duke.edu/display/OITSLP/JMP+Clinical
Summary of wiki: OIT already centrally funds JMP, but may not be able to assume the additional cost of adding JMP Clinical to the license. The cost to add this product to our license is modest, and the cost could be recovered very easily if a few departments chip in. We could also test out a pay-by-license model (like with SAS) with little risk depending on how much individual users of JMP clinical are willing to spend per license.
